When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Neuroblastoma

Last reviewed: 6 Apr 2025
Last updated: 31 Jan 2025

Summary

Definition

History and exam

Key diagnostic factors

  • age <4 years
  • abdominal distension
  • abdominal mass
  • pain
  • decreased appetite
  • weight loss
  • fussiness (infants)
  • fatigue
  • periorbital ecchymosis (raccoon eyes)
  • subcutaneous skin nodules
  • family history of neuroblastic tumors
  • signs of spinal cord compression
  • signs of Horner syndrome
  • signs of superior vena cava syndrome
  • intractable secretory diarrhea
  • opsoclonus-myoclonus ataxia (OMA)
Full details

Other diagnostic factors

  • constipation
  • pallor
  • bleeding
  • infections
  • hypertension
  • hepatomegaly
Full details

Risk factors

  • neurocristopathies or other syndromes
  • family history of neuroblastic tumors or genetic predisposition
Full details

Diagnostic tests

1st tests to order

  • CBC
  • serum electrolytes
  • serum creatinine/BUN
  • liver function tests (LFTs)
  • serum lactate dehydrogenase (LDH)
  • urine catecholamines
  • ultrasound abdomen
  • CT scan
  • MRI scan
Full details

Tests to consider

  • tumor biopsy
  • bilateral bone marrow aspiration and biopsy
  • serum vasoactive intestinal peptide (VIP)
  • 123-iodine-metaiodobenzylguanidine (MIBG) scintigraphy
  • positron emission tomography with 18-F-deoxyglucose (18F-FDG PET)
Full details

Treatment algorithm

ACUTE

low-risk disease

intermediate-risk disease

high-risk disease

ONGOING

relapsed or refractory disease

Contributors

Authors

Jason Shohet, MD, PhD

Associate Professor

University of Massachusetts

Chan Medical School

Worcester

MA

Disclosures

JS declares that he has no competing interests.

Jennifer Foster, MD, MPH

Clinical Director, Neuroblastoma Program

Associate Professor

Department of Pediatrics Section of Hematology/Oncology

Texas Children's Cancer Center

Baylor College of Medicine

Houston

TX

Disclosures

JF has served on the advisory board for Y-mAbs Therapeutics and Fennec Pharmaceuticals.

Peer reviewers

Juliet C Gray, MB, BS, MA, MRCPCH, PhD

Associate Professor and Consultant in Paediatric Oncology

University of Southampton

Southampton

UK

Disclosures

JCG declares that she has no competing interests.

Daniel Weiser, MD

Medical Director, Intra-Abdominal Solid Tumor Program

Children's Hospital at Montefiore

Assistant Professor, Departments of Pediatrics & Genetics

Albert Einstein College of Medicine

Bronx

NY

Disclosures

DW declares that he has no competing interests.

David Ziegler, MBBS, BSc (Med), FRACP, MD/PhD

Senior Staff Specialist

Sydney Children’s Hospital

Randwick

Sydney

Australia

Disclosures

DZ declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct;261(1):243-57.Full text  Abstract

National Comprehensive Cancer Network. Neuroblastoma [internet publication].Full text

Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-7.Full text  Abstract

Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the Children's Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-41. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Neuroblastoma images
  • Differentials

    • Wilms tumor
    • Ewing sarcoma
    • Rhabdomyosarcoma
    More Differentials
  • Guidelines

    • NCCN clinical practice guidelines in oncology: neuroblastoma
    • Revisions to the International Neuroblastoma Response Criteria
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer